First Trust NYSE Arca Biotechnology Index Fund
U.S. stock index ETF · tracks NYSE Arca Biotechnology Index
As of its 2026 Q2 report, First Trust NYSE Arca Biotechnology Index Fund held 32 positions with $2.81B in net assets. Its ten largest holdings made up 43.2% of the fund. The FBT share class costs 0.55% a year. Over the 12 months to May 2026, FBT returned 38.3%, with dividends reinvested. In 2026 Q2 it added 2 new positions and exited 2.
The First Trust NYSE Arca Biotechnology Index Fund (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the NYSE Arca Biotechnology Index (the Index ).
The fund tracks the NYSE Arca Biotechnology Index, an equal-weighted benchmark of 30 biotechnology companies selected and rebalanced quarterly based on net sales, the ratio of sales to R&D spending, and R&D spending growth, with a cap of 6 holdings in biotech tools and diagnostics. The fund holds all index constituents and will experience higher portfolio turnover due to quarterly reconstitution. Because the index is reconstituted quarterly, the fund's holdings and weightings will shift accordingly.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
5.60% | $157.46M | 1.8M | $86.95 | |
5.12% | $144.00M | 9.9M | $14.59 | |
VCYTVERACYTE INC | 5.10% | $143.37M | 2.4M | $58.73 |
BRKRBRUKER CORP | 4.32% | $121.51M | 2.0M | $60.18 |
ALKERMES PLC | 4.24% | $119.20M | 2.3M | $52.39 |
ILMNILLUMINA INC | 3.92% | $110.35M | 627.6K | $175.83 |
3.87% | $108.91M | 293.0K | $371.67 | |
NTRANATERA INC | 3.79% | $106.73M | 393.2K | $271.45 |
3.71% | $104.30M | 426.1K | $244.77 | |
3.53% | $99.24M | 588.8K | $168.53 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
All 32 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 100.01% |
| Cash & short-term | 0.05% |
By sector
- Health Care
- 87.3%
- International
- 12.6%
- Cash
- 0.1%
- Other
- 0.0%
How it has done
FBT share class · total returns with dividends reinvested
Volatility over the last 12 months: 16.73%. Past returns are a record, not a forecast.
Jun 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Fees & fund details
First Trust NYSE Arca Biotechnology Index Fund is a U.S. equity index ETF that tracks the NYSE Arca Biotechnology Index. 48% of FBT’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 84% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Index (passive)
- Fund type
- ETF
- Expense ratio, by class
- 0.55%· FBT 0.55%
- Portfolio turnover
- 37.00% a year · as of 2026 Q2
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
2 new
2 exited
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — FBT, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”